Bin Zou

Bin Zou, Ph.D. is the Founder and Chief Executive Officer of Axcynsis Therapeutics, a Singapore-based biotechnology company pioneering next-generation antibody-drug conjugate (ADC) therapies for cancer. He also serves as Chairman of the company and brings deep experience in drug discovery and biotech leadership, including roles as Managing Director at Trinity Innovation Bioventure Singapore and CEO of Shanghai Blueray Biopharma. Previously, Dr. Zou was a Principal Scientist at Novartis Institute for Tropical Disease and has authored over 25 peer-reviewed publications. Additionally, he holds academic roles such as Adjunct Associate Professor at the National University of Singapore